This Canadian Company Is Quietly Building a Berkshire-Like Model. Is the Stock a Buy Now?

Brookfield Corporation is presented as a capital-ownership and compounding platform rather than a traditional asset manager, with more than $1 trillion in third-party assets, $180 billion on balance sheet, and $135 billion in insurance assets. The article highlights roughly $3 billion in annual fee-related earnings growing at over 20% year over year, plus $1.6 billion of distributable earnings from infrastructure, renewable power, and insurance in Q4 2025. The tone is constructive, arguing that the company’s improving earnings mix and long-duration capital could support a Berkshire Hathaway-like compounding model.

Analysis

BN’s core debate is no longer whether it is an asset manager, but whether the market is correctly capitalizing a hybrid balance sheet plus permanent capital platform. The second-order effect is that a larger share of value can migrate from volatile mark-to-market realizations into recurring fee-related earnings and spread income from insurance float, which should compress the discount rate investors apply to the company over time. That transition matters more than headline AUM growth because it improves funding durability and reduces forced-seller risk in weak markets.

The key competitive advantage is not scale alone; it is duration. A firm that can hold infrastructure, renewables, and private assets through dislocations can buy optionality when peers are liquidity constrained, creating a cycle where future IRR is boosted by countercyclical deployment rather than exit timing. That is precisely the sort of structural edge BRK.B has historically monetized, but in BN’s case the market may be underappreciating how insurance assets and fee-bearing capital interact to create a self-reinforcing capital engine.

The main risk is that the market’s skepticism is partly justified: complexity can mask dependence on capital markets, and any stumble in spread income, underwriting, or realizations could expose the business to multiple compression before the compounding story is obvious. Over the next 6-18 months, the stock likely trades more on perceived quality of earnings than on reported asset growth; a surprise slowdown in fee-related earnings or a weaker insurance deployment cycle would be the cleanest way to break the thesis. Conversely, continued >20% fee-related earnings growth plus visible insurance scale-up should force a re-rating as investors begin to model BN less like an opaque alternative manager and more like a long-duration compounding vehicle.

Key Decisions for Investors

• Initiate/maintain a long BN position on 6-12 month horizon; use weakness tied to market de-risking or earnings noise as entry, with the thesis anchored on rerating of recurring earnings rather than near-term realizations.
• Pair trade: long BN / short a higher-beta listed asset manager with more transaction-dependent earnings over the next 6-9 months; the relative value case is that BN’s recurring fee and insurance mix should prove more resilient in a choppy funding environment.
• Buy BRK.B vs BN as a conservative expression of the same 'permanent capital' theme if the goal is lower execution risk; BN offers higher upside but also a longer path to market trust, while BRK.B is the cleaner quality benchmark.
• Avoid chasing BAM purely on headline AUM momentum; for the next 1-2 quarters, the better signal is whether BN’s insurance and balance-sheet capital can keep compounding without increasing leverage or impairing liquidity.
• If BN rerates sharply on the next print, consider monetizing upside via covered calls 3-6 months out; the stock can remain structurally attractive while short-term multiple expansion may outpace fundamentals.